I am a
Home I AM A Search Login

Papers of the Week

2021 Jun 25

Zhongguo Gu Shang



[Current advances in research of semaphorin 3A:a potential target for the treatment of nospecific low back pain].


Xin L, Xu W-X, Wang J, Song H-P, Liu J, Wang J, Fan S-W, Yang Y
Zhongguo Gu Shang. 2021 Jun 25; 34(6):589-92.
PMID: 34180183.


Nonspecific low back pain is closely associated with afferent nerve ingrowth into degenerated IVDs and increasing the inflammatory response. Members of the class 3 semaphorins signal their response through two prominent receptors; the NRP (Neuropilin-1) and the Plexin A. Sema3A (Semaphorin3A) is primarily known for their role in modulating neuronal survival as well as neurite outgrowth and guidance via regulation of Sema3A-NRP-1-plexinA signal pathway. Also, sema3A is shown to be conductive to innervate the inner painful degenerated IVDs (Intervertebral discs). Furthermore, sema3A is thought to act as a barrier to endothelial cells survival and migration on vascular endothelial growth factor (VEGF) and inhibition of KLF5-induced (Krüppel-like factor 5) inflammatory mediators within degenerated IVDs. Therefore, Sema3A produce a new perspective of dual-action therapeutic agent for attenuating the regulator of innervation and angiogenesis into degenerated IVDs and inhibition of KLF5-induced inflammation.